Friday, July 29, 2016, 42 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4,615.18 to $19,888,560.00.

Highlighted Stocks Traded by Insiders:

Autodesk (ADSK) - FREE Research Report

Di Fronzo Pascal W, who is SVP, General Counsel at Autodesk, sold 400 shares at $59.46 on July 29, 2016. Following this transaction, the SVP, General Counsel owned 85,500 shares meaning that the stake was reduced by 0.47% with the 400-share transaction.

The shares most recently traded at $59.52, up $0.06, or 0.1% since the insider transaction. Historical insider transactions for Autodesk go as follows:

  • 4-Week # shares sold: 26,209
  • 12-Week # shares sold: 41,972
  • 24-Week # shares sold: 144,110

The average volume for Autodesk has been 1.8 million shares per day over the past 30 days. Autodesk has a market cap of $13.4 billion and is part of the technology sector and computer software & services industry. Shares are down 2.43% year-to-date as of the close of trading on Friday.

Autodesk, Inc. operates as a design software and services company worldwide. Currently, there are 7 analysts who rate Autodesk a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADSK - FREE

TheStreet Quant Ratings

rates Autodesk as a

hold

. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full

Autodesk Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bellicum Pharmaceuticals (BLCM) - FREE Research Report

Spencer David M., who is Chief Scientific Officer at Bellicum Pharmaceuticals, sold 10,000 shares at $15.00 on July 29, 2016. Following this transaction, the Chief Scientific Officer owned 176,082 shares meaning that the stake was reduced by 5.37% with the 10,000-share transaction.

The shares most recently traded at $16.32, up $1.32, or 8.09% since the insider transaction. Historical insider transactions for Bellicum Pharmaceuticals go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares sold: 50,000

The average volume for Bellicum Pharmaceuticals has been 333,200 shares per day over the past 30 days. Bellicum Pharmaceuticals has a market cap of $425.0 million and is part of the health care sector and drugs industry. Shares are down 21.66% year-to-date as of the close of trading on Friday.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Currently, there are 3 analysts who rate Bellicum Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLCM - FREE

TheStreet Quant Ratings

rates Bellicum Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Bellicum Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LKQ (LKQ) - FREE Research Report

Wagman Robert L, who is President and CEO at LKQ, sold 20,100 shares at $34.07 on July 29, 2016. Following this transaction, the President and CEO owned 360,156 shares meaning that the stake was reduced by 5.29% with the 20,100-share transaction.

The shares most recently traded at $34.42, up $0.35, or 1.01% since the insider transaction. Historical insider transactions for LKQ go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 16,805
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 28,902
  • 24-Week # shares bought: 16,500
  • 24-Week # shares sold: 29,972

The average volume for LKQ has been 3.1 million shares per day over the past 30 days. LKQ has a market cap of $10.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 16.06% year-to-date as of the close of trading on Friday.

LKQ Corporation, together with its subsidiaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, and internationally. It operates in three segments: North America, Europe, and Specialty. The company has a P/E ratio of 24.2. Currently, there are 9 analysts who rate LKQ a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LKQ - FREE

TheStreet Quant Ratings

rates LKQ as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

LKQ Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.